Jeff Yass’s INmune Bio INMB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$46.9K Sell
28,800
-2,500
-8% -$3.46K ﹤0.01% 12852
2026
Q1
$35.4K Sell
31,300
-27,700
-47% -$39.5K ﹤0.01% 12723
2025
Q4
$92K Sell
59,000
-96,600
-62% -$172K ﹤0.01% 11498
2025
Q3
$322K Sell
155,600
-160,500
-51% -$367K ﹤0.01% 9944
2025
Q2
$730K Buy
316,100
+259,300
+457% +$1.9M ﹤0.01% 8254
2025
Q1
$444K Buy
56,800
+31,700
+126% +$252K ﹤0.01% 9156
2024
Q4
$117K Buy
+25,100
New +$131K ﹤0.01% 11217
2024
Q3
Sell
-39,400
Closed -$348K 12470
2024
Q2
$348K Buy
+39,400
New +$388K ﹤0.01% 9129
2024
Q1
Sell
-24,600
Closed -$277K 12712
2023
Q4
$277K Sell
24,600
-14,100
-36% -$118K ﹤0.01% 9988
2023
Q3
$265K Buy
38,700
+4,900
+14% +$40.6K ﹤0.01% 9634
2023
Q2
$307K Buy
+33,800
New +$271K ﹤0.01% 9387
2022
Q4
Sell
-19,600
Closed -$122K 13007
2022
Q3
$122K Buy
+19,600
New +$172K ﹤0.01% 11500
2021
Q4
Sell
-42,900
Closed -$833K 13472
2021
Q3
$833K Buy
+42,900
New +$828K ﹤0.01% 8030

Other funds holding INMB

Jeff Yass's INMB Position: Q2 2026 in Review

Jeff Yass reduced its INmune Bio (INMB) stake by 18% in Q2 2026, selling an estimated $49.7K and leaving 158,452 shares worth $258K. The position accounts for ﹤0.01% of the portfolio, ranked #11379.

Jeff Yass first reported a position in INMB in Q1 2020 and has held it in 21 quarters since. The position peaked at $1.82M in Q1 2024. 83 funds tracked by Wall St. Rank hold INMB as of Q2 2026.

  • Jeff Yass held 158,452 shares of INmune Bio worth $258K as of Q2 2026.
  • Jeff Yass sold 35,939 INmune Bio shares in Q2 2026, an estimated $49.7K.
  • INmune Bio made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #11379 holding.
  • Jeff Yass first reported a position in INmune Bio in Q1 2020 and has held it in 21 quarters since.
  • Jeff Yass's INmune Bio position peaked at $1.82M in Q1 2024.
  • 83 funds tracked by Wall St. Rank held INmune Bio as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.